anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The extent of bone mass built up during childhood and adolescence is the most important determinant of osteoporosis later in life. Some disabled children, such as those with cerebral palsy, are particularly vulnerable to low bone mass accumulation due to decreased mobility and weight-bearing. These children also have poor muscle strength and control, which limits function and contributes to the lack of mechanical stimulation needed to build bone mass. The most common treatment for these children is physical therapy, which is time- and labor-intensive and may not be adequately available to them. Whole body vibration has shown promise as an alternative method for stimulating increases in bone mass and improvements in muscle. The purpose of this study is to evaluate the effects of high frequency, low magnitude vibration on bone and muscle in children with cerebral palsy. This intervention may be useful as a noninvasive, nonpharmacological treatment for low bone mass and poor muscle function in these children.

This study will last 1 year. All participants will visit the hospital 3 times, at study entry and Months 6 and 12. At each visit, height and weight will be measured, muscle strength and balance will be tested, and bones and muscles in the spine and lower leg will be imaged with computed tomography (CT), a special x-ray machine. Participants will be randomly assigned to one of two groups. For this study, all participants will be asked to stand for 10 minutes every day for 1 year. For Group 1, a vibrating platform will be used for the 10-minute standing sessions during the first half of the study but not during the second half of the study. For Group 2, this will be reversed and the vibrating platform will not be used during the first half of the study but will be used during the second half of the study.
Participants will receive 200mg DHA to take per day. Participants will be asked to take four capsules containing 50mg DHA each.
BACKGROUND: While ceftriaxone resistance remains scarce in Switzerland, global Neisseria gonorrhoeae (NG) antimicrobial resistance poses an urgent threat. This study describes clinical characteristics in MSM (men who have sex with men) diagnosed with NG infection and analyses NG resistance by phenotypic and genotypic means.
METHODS: Data of MSM enrolled in three clinical cohorts with a positive polymerase chain reaction test (PCR) for NG were analysed between January 2019 and December 2021 and linked with antibiotic susceptibility testing. Bacterial isolates were subjected to whole genome sequencing (WGS).
RESULTS: Of 142 participants, 141 (99%) were MSM and 118 (84%) living with HIV. Participants were treated with ceftriaxone (N = 79), azithromycin (N = 2), or a combination of both (N = 61). No clinical or microbiological failures were observed. From 182 positive PCR samples taken, 23 were available for detailed analysis. Based on minimal inhibitory concentrations (MICs), all isolates were susceptible to ceftriaxone, gentamicin, cefixime, cefpodoxime, ertapenem, zoliflodacin, and spectinomycin. Resistance to azithromycin, tetracyclines and ciprofloxacin was observed in 10 (43%), 23 (100%) and 11 (48%) of the cases, respectively. Analysis of WGS data revealed combinations of resistance determinants that matched with the corresponding phenotypic resistance pattern of each isolate.
CONCLUSION: Among the MSM diagnosed with NG mainly acquired in Switzerland, ceftriaxone MICs were low for a subset of bacterial isolates studied and no treatment failures were observed. For azithromycin, high occurrences of in vitro resistance were found. Gentamicin, cefixime, cefpodoxime, ertapenem, spectinomycin, and zoliflodacin displayed excellent in vitro activity against the 23 isolates underscoring their potential as alternative agents to ceftriaxone.
There are many Canadians who need an organ transplant and who will never get one. In the past, people could only be organ donors after being declared brain dead.

The dead donor rule serves this purpose by ensuring that death determination precedes organ retrieval. In Canada, death determination occurs in one of two ways. In neurologic determination of death (NDD), death is declared upon completion of a standardized neurologic assessment that confirms permanent loss of brain activity. In donation after circulatory determination of death (DCDD), death is declared 5 minutes after circulatory arrest. By confirming permanent loss of brain activity, the current NDD process protects donors from suffering and maintains stakeholder trust. In contrast, the current DCDD process assumes, but does not explicitly confirm, permanent loss of brain activity when death is declared 5 minutes after circulatory arrest. While this assumption is rooted in a strong physiologic rationale, lack of compelling evidence regarding cessation of brain activity in humans contributes to ongoing mistrust of the DCDD process among healthcare and public stakeholders.
In this study participants will be asked to participate in a training study to examine whether a new walking intervention that combines cognitive training with walking on a treadmill improves walking more than gait training or cognitive training alone. Participants with Parkinson's disease (PD) will come to the lab for a complete gait assessment using a motion analysis system that will record leg motion and muscle activity during comfortable walking. During the initial evaluation, participants will also complete cognitive assessments and surveys about community activities and quality of life related to PD. Participants will be divided into two training groups and asked to come to the lab three times a week for four weeks during the intervention. One week and one month after training, participants will return to the lab to complete all the same assessments that were performed during the initial visit. The results of the three testing sessions (initial, one week and one month) will be compared between and within groups to see if any of the interventions provided unique benefits to the health of persons with PD.
Taurolidine (taurolin; tauroline; 4,4'-methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide) has been found to be an effective agent for treating patients inflicted with monocytic and/or myeloid leukemias through the induction of apoptosis in leukemia cells. Concentrations of taurolidine in the range of 50 to 100 νg/ml induced apoptosis in 75 % of peripheral blood monocytes incubated in culture medium within six hours. Further, 100 νg/ml taurolidine induced apoptosis in 92 % of granulocytes incubated in culture medium within six hours. Taurolidine was also effective in reducing the hypercoagulable state associated with tissue factor expression on leukemia cells, providing a means by which the incidence and degree of severity of coagulopathies associated with tissue factor expression can be reduced in leukemia patients. Preferred therapeutic dosages for treatment of leukemias are from about 10 to about 500 mg/kg body weight. Most preferred is a dose that results in a 200 νg/ml concentration in the plasma, which is typically about 150 mg/kg body weight.
Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
The proposed protocol includes a part of aerobic training and a subsequent part of strengthening exercises for large muscle groups. The total duration of each session will be approximately 30 minutes. There are 2 weekly training sessions for 3 months.
During their infants' 6-month check-up, parents will be administered a demographic survey, the Karitane Parental Self-Efficacy Scale, the Behavioral Pediatric Feeding Assessment Scale, the Edinburgh Postnatal Depression Scale, and the Generalized Anxiety Disorder-7 scale. The Father-Infant Bonding Scale will be administered exclusively to fathers during the same visit. Subsequently, both mothers and fathers in this group will receive complementary feeding education.
Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
Single arm. All patient seen face-to-face and then with 3D telemedicine.
Disclosed is a method for evaluating the effectiveness of a health programme. The method includes: (i) selecting type of activity on a computer; (ii) entering and awarding scores for each activity on a computer; (iii) analysing the scores by a computer programme; (iv) recording activity periodically on the computer; (v) recording results of the health programme; (vi) analysing results of programme; and (vii) evaluating the results. Evaluating the results includes monitoring the effectiveness of the health programme by recording daily activities and entering a score for each activity. The score for each activity is based on a set of daily challenges consisting of the following: (i) to undertake >30 minute exercise; (ii) to complete flexibility exercises; (iii) to eat a healthy breakfast; (iv) to eat a wholesome lunch; (v) to eat a balanced dinner; (vi) to eat only healthy (or no) snacks; (vii) to consume no alcohol or drugs; (viii) to not smoke; (ix) to spend > 30 minutes with ones family; and (x) to spend > 30 minutes for/on oneself. The score records a point for each uncompleted activity over 7 days each week over a series of weeks, then the score is recorded as an average for each week. The method also includes: (viii) processing the results to generate the score card wherein the score recorded over a series of weeks is represented in graphic form.
BACKGROUND: Insulin resistance has been correlated with the genetic diversity within the insulin-like binding proteins genes. Moreover, insulin resistance is one of the key characteristics of the widespread reproductive endocrine condition known as polycystic ovarian syndrome (PCOS). Hence, this study is aimed to determine the association between IGFBP3 and IGF2BP2 gene variants and PCOS risk.
METHODS: A total of 300 subjects (150 PCOS cases diagnosed based on Rotterdam ESHRE/ASRM consensus criteria and 150 healthy subjects) were recruited in this case-control cross-sectional study. Tetra-primer amplification refractory mutation system polymerase chain reaction (ARMS-PCR) was used for genotyping rs11705701, whereas genotyping of rs1470579 and rs2854744 was done employing PCR-restriction fragment length polymorphism (PCR-RFLP) technique.
RESULTS: The CC and AA+AC genotypes of rs1470579 conferred an increased risk of PCOS in our population. Regarding the rs2854744, an increased risk of PCOS was observed under the codominant homozygous (TT vs. GG) model by 2.54 fold. The C allele of rs1470579 and T allele of rs2854744 enhanced PCOS risk by 1.97 and 1.46 folds, respectively. Haplotype analysis showed that the Ars1470579Ars11705701 haplotype conferred a decreased risk of PCOS (odds ratio = 0.53, 95% confidence interval = 0.34-0.83, p = 0.006). The AC/GG/GT, AA/GA/GT, AC/GA/GG, and AC/GA/GT genotype combinations of rs1470579/rs11705701/rs2854744 were associated with a decreased risk of the disease.
CONCLUSIONS: IGF2BP2 rs1470579 and IGFBP3 rs2854744 enhanced PCOS susceptibility in a Southeastern Iranian population. Further investigation involving larger cohorts representing diverse ethnic backgrounds is needed to confirm the current findings.
A randomized, double blind, controlled trial will be conducted in intensive care unit (ICU) and neurosurgery ward, in Shohada-E-Tajrish hospital,Tehran, Iran. First, patients will be carefully checked for inclusion and exclusion criteria. Then, the eligible patients will complete the consent form for this study. 60 eligible brain tumor patients diagnosed by surgeon that are ready for craniotomy will be selected.These patients will be divided into two groups. Intervention group will be received an intramuscular (IM) single dose of vitamin D (300000 IU),while another group will not receive. Pain in patients will be checked daily by up to 3 days after surgery. Finally, the VAS pain score will be compared in both groups.
Beta-adrenergic agonists may produce significant hypokalemia in some patients, which has the potential to produce adverse cardiovascular effects [see Clinical Pharmacology (12.2)]. The decrease in serum potassium is usually transient, not requiring supplementation. Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.

In patients with severe COPD, hypokalemia may be potentiated by hypoxia and concomitant treatment [see Drug Interactions (7.2)], which may increase the susceptibility for cardiac arrhythmias.

Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of STRIVERDI RESPIMAT with the rates similar to those for placebo controls. STRIVERDI RESPIMAT has not been investigated in patients whose diabetes mellitus is not well controlled.
The invention discloses a preparation method and applications of dispersing tablets containing pidotimod, belonging to a new technical field of medicament and relating to a new medicament form of pidotimod. The dispersing tablets are used to treat 1) repeated upper and lower respiratory tract infections (pharyngitis, tracheitis, bronchitis, tonsillitis); 2) repeated infection of otorhinolaryngology (rhinitis, nasosinusitis, otitis); 3) urinary tract infections; 4) gynae infections; 5) clinic patients with low cellular immune function after chemotherapy. The dispersing tablets are used to decrease times of acute attacks, shorten course of the disease and lessen attack degree, and also can be used as adjuvant therapy for antibiotics in case of an acute attack. The new medicament form is characterized in that the tablets are disintegrated into small granules when meeting with water, and the granules are uniformly dispersed and can pass through the A No. 2 screen (24 meshes). The medicament with relatively low dosage and poor water solubility can obviously enhance absorption in body and improve bioavailability after being made into dispersing tablets.
The invention relates to a compilation comprising at least five different peptides, each peptide comprising at least one sequence element corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1 - 354. The invention further relates to an  in vitro  method for determining a patient's immune status to soybean allergens, to a method for detecting at least one soybean allergen in a substance and to a method for determining the allergenicity of a soybean variety. Additionally, the invention relates to a kit comprising at least one composition containing a compound comprising at least two identical and/or different sequence elements each corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1 - 354. Furthermore, the invention relates to the use of a peptide comprising a sequence element corresponding to an epitope for providing a molecule binding to a protein or peptide comprising the epitope.
A body empowerment program rooted in the psychological theory of cognitive dissonance has been shown to be effective to reduce the value of the thin beauty ideal. This theory proposes that humans are motivated to maintain consistency in their beliefs and actions, and inconsistencies will result in psychological discomfort (or cognitive dissonance). A shift in beliefs or actions is required to resolve this discomfort and maintain consistency. However, the accessibility of this program is lacking. The proposed study will examine the effectiveness of a single session, virtually delivered body empowerment program designed to create cognitive dissonance by asking participants to identify cultural norms surrounding appearance and attractiveness, then challenge these ideals through a series of interactive activities in a fully virtual, self-paced module. Challenging these ideals (e.g., identifying how ideals represent very narrow identities and are informed by oppressive value systems, stating the psychological costs of trying to change your body to match ideals) theoretically creates cognitive dissonance in those who have internalized the value of pursuing those ideals. This dissonance is resolved through a reduced investment in the ideals and then hypothesized to lead to more positive attitudes about body image, dieting, and other unhealthy weight control behaviors. The program consists of a single 45-minute self paced, interactive, virtual module. Primary assessments will be completed at pre-intervention and post-intervention.
Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
The present invention relates to an antibacterial composition comprising a Selaginella extract as an active ingredient. The Selaginella extract has an antibacterial effect with respect to Staphylococcu aureus, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Chaetomium globosum, Aspergillus brasiliensis, Trichoerma virens, Penicilium funiculosum, and Aureobasidium pullulans. Thus, a composition comprising a Selaginella extract according to the present invention serves as a natural preservative and has an antibacterial activity with respect to strains included in, in particular, the regulations of cosmetic products. Therefore, the composition of the present invention can be used as a natural preservative in the field of cosmetics or other fields requiring antibacterial activities. The Selaginella extract is composed of naturally derived components, and is thus safe to a human body, does not irritate skin, and has stable antibacterial efficacy. Thus, the Selaginella extract can be useful in the food, daily necessities, and cosmetic industries without limitation.
PURPOSE:To obtain a film preparation directly bondable to an intraoral affected part, having proper durability, comprising a water-soluble polymer film containing pharmaceutical activity. CONSTITUTION:A compound having pharmaceutical activity, especially percutaneously absorbable active component, is added to a water-soluble polymer (e.g. hydroxypropyl cellulose or hydroxypropylmethyl cellulose), which is made into a film by casting method or rolling method to give an intraoral patch type film preparation. The thickness of polymer film is 0.20-0.30mm, preferably 0.24-0.26mm. By providing at least one surface of the film with an adjusting layer, a film preparation having a controlled amount of active ingredient released is obtained. Gelatin, guar gum, etc., is used as the adjusting layer for the purpose of adjusting water permeability and polyvinyl acetal diethylaminoacetate is used for adjusting pH dependence.
FIELD: pharmacy. SUBSTANCE: invention proposes a pharmaceutical composition for rectal administration as suppository. The composition has 1,2,3,9-tetrahydro-9-methyl- -3-[(2-methyl-1H-imidazole-1-yl)-methyl] -4H-carbazole-4-one as an active component in the form of free base or a pharmaceutically acceptable solvate. A pharmaceutically acceptable carrier is a solid-fat base exhibiting a hydroxyl number at the range 60-70. The amount of the indicated active component is from 0.05 to 20% by mass. For preparing the composition as suppository the indicated active component is mixed thoroughly with the indicated carrier. The composition is used for treatment of patients with states caused by effect of 5-hydroxytryptamine on 5-ГТ 3 -receptors. The indicated states are nausea and vomiting. EFFECT: enhanced effectiveness of treatment. 6 cl, 9 ex
Provided herein are compositions and methods that allow for the study of HIV latency and reactivation. Further provided are compositions and methods for in vitro screening of agents for their ability to reactivate, suppress reactivation or inhibit transcription of HIV. Compositions for and methods for activating a cell are also provided herein. Further provided herein are methods of treating a subject using agents that reactivate latent HIV infection or agents that inhibit HIV transcription. Also provided herein are methods of activating a latent microbiological entity in a subject. Further provided herein are methods for enhancing an immune response in a subject and compositions used as a vaccination adjuvant. Methods of making disclosed cells and compositions are also provided herein.
Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
LYRICA treatment was associated with creatine kinase elevations. Mean changes in creatine kinase from baseline to the maximum value were 60 U/L for LYRICA-treated patients and 28 U/L for the placebo patients. In all controlled trials in adult patients across multiple patient populations, 1.5% of patients on LYRICA and 0.7% of placebo patients had a value of creatine kinase at least three times the upper limit of normal. Three LYRICA-treated subjects had events reported as rhabdomyolysis in premarketing clinical trials. The relationship between these myopathy events and LYRICA is not completely understood because the cases had documented factors that may have caused or contributed to these events. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if these muscle symptoms are accompanied by malaise or fever. Discontinue treatment with LYRICA if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur.